TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter Hoang, will participate in a panel discussion and give a company presentation at the 2018 Sachs Associates Immuno-Oncology BD&L and Investment Forum, held June 1, 2018 at the Waldorf Astoria Chicago Hotel.
Immuno-Oncology BD&L and Investment Forum
TapImmune Company Presentation
Advances in Cell and Gene Therapies Panel
Date: Friday, June 1, 2018
Time: 12:20 p.m. Central
Location: Track A
The Backstory: In May 2018, the Company announced a merger agreement with Marker Therapeutics, creating a transformational immuno-oncology platform. This merger adds a multi-antigen targeted cell therapy platform to TPIV's peptide vaccine portfolio, and it has the potential to disrupt the CAR-T and TCR filed therapies. TPIV's acquired therapies are significantly less toxic than CAR-T, require no gene modification, and are highly effective and extremely durable, without the need for lympho-depletion.
Disclosure
(TapImmune Inc. [NASDAQ: TPIV] is a client of RedChip Companies, Inc. TPIV agreed to pay RedChip Companies, Inc., a monthly cash fee of RedChip investor awareness services. and consulting services.)
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has signed a definitive agreement to acquire Counsyl, a pioneer in expanded carrier screening and non-invasive prenatal screening for $375 million through a combination of cash and Myriad common stock. Counsyl has experienced rapid growth since being founded in 2007, and in the last 12 months alone has generated more than $134 million in revenue and performed over 280,000 reproductive genetic tests.
Key Quote: “By offering Counsyl’s best-in-class reproductive testing products in conjunction with Myriad’s leading hereditary cancer tests, we are well positioned to be the premier women’s health genetic testing company.” Mark C. Capone, President and CEO of Myriad Genetics.
The Backstory: Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted adviser, transforming patients’ lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that (1) determine the risk of developing disease, (2) accurately diagnose disease, (3) assess the risk of disease progression, and (4) guide treatment decisions across six major medical specialties, where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five strategic imperatives: (1) building upon a solid hereditary cancer foundation, (2) growing new product volume, (3) expanding reimbursement coverage for new products, (4) increasing RNA kit revenue internationally, and (5) improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company’s website: www.myriad.com.
The Brink’s Company (NYSE: BCO), the world leader in total cash management and secure logistics, today announced that Doug Pertz, president and chief executive officer, and Ron Domanico, executive vice president and chief financial officer, will participate in the Baird 2018 Global Consumer, Technology & Services Conference on June 5, 2018, at the InterContinental New York Barclay Hotel in New York City. The company’s presentation is scheduled to begin at 12:15 p.m. Eastern.
The Backstory: The Brink’s Company is the world leader in total cash management and secure logistics, including cash-in-transit, ATM services, vault outsourcing, money processing, intelligent safe services, international transportation of valuables, and payment services. Our customers include financial institutions, retailers, government agencies, mints, jewelers, and other commercial operations. Our global network of operations in 41 countries serves customers in more than 100 countries. For more information, please visit our website at www.Brinks.com, or call (804) 289-9709.
Canopy Growth (NYSE: CGC) Began Trading on NYSE on May 24
Canopy Growth (NYSE: CGC; TSX: WEED), a world-leading diversified cannabis and hemp company, began trading on the New York Stock Exchange last week under the ticker CGC.
Why It Matters: CGC is the first cannabis company to trade on the NYSE. This is a major milestone for the industry and further improves perceptions of the rapidly expanding, multi-billion-dollar market for legal recreational and medical marijuana.
Key Quote: "Five years ago, as a small Smiths Falls based startup in the cannabis sector, we could have never imagined this historic moment. I am exceptionally proud of our team for what they have built and what we will continue to build by continuing our focus on research, product innovation, and intellectual property to drive the industry forward around the world." – Bruce Linton, Chairman & CEO
What’s Next: CGC has established partnerships with leading sector names, including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name a few. They operate eight cannabis production sites with over 2.4 million square feet of production capacity, including over 500,000 square feet of GMP-certified production space. The scale of CGC makes it the bellwether stock of the space, and this listing bodes well not just for CGC, but for all cannabis stocks.
Aimmune Therapeutics Inc. (NASDAQ: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that data from a new study on the psychosocial burden of peanut allergy in European countries were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018 in Munich.
The Backstory: The APPEAL (Allergy to Peanuts Impacting Emotions and Life) study is a multi-dimensional, multi-phase effort, led by Aimmune Therapeutics in partnership with an expert panel of European food-allergy patient-advocacy group leaders and healthcare professionals (psychologists, dieticians and allergists), to learn about the psychosocial burden of peanut allergy. Audrey DunnGalvin, Ph.D., of University College Cork, Ireland, discussed the data in a late-breaking oral presentation.
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for potentially life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4–17 years of age and is currently being evaluated in Phase 3 clinical trials. For more information, please see www.aimmune.com.
Why It Matters: In a quantitative online survey conducted in eight European countries, the APPEAL study examined the impact of peanut allergy on peanut-allergic children (as reported by a parent or caregiver), parents and caregivers of peanut-allergic children, and peanut-allergic adults. The survey showed that peanut allergy has a daily impact on more than 80% of those children, parents/caregivers and adults, and 40% live with a high level of uncertainty. Additionally, 77% of peanut-allergic individuals have been made to feel different (negatively), and 43% have been affected by bullying.
Key Quote: “Aimmune is committed to learning from people’s experiences with food allergies and applying those insights to our efforts to develop approved therapeutics. The work and results of the APPEAL collaboration have been especially inspiring. Many of the patient advocacy group leaders involved have first-hand experience with food allergy, and their insights on behalf of the community were a tremendous help in identifying key issues to query. We also benefited greatly from the expertise of the team’s healthcare professionals, who generously shared the knowledge they have amassed. Foremost, we are grateful to the many hundreds of people who responded to the survey so that we can better understand the challenges peanut-allergic individuals and their families face every day. We look forward to continuing to deepen that understanding.” Sue Barrowcliffe, General Manager, Aimmune Europe
According to Matthew Johnson, an analyst and contributor to Investopedia, the recent strength of small-caps indicate that ultimately large caps are heading higher too.
Peter Costa, president of Empire Trading, an NYSE trading firm, commented on CNBC last Thursday, “You’ll never see a bear market start with the Russell 2000 hitting an all-time high.”
For perspective, as of May 22, the Russell 2000 was up 6.6% year-to-date, while the S&P 500 was up just 2.2%.
B. Riley’s Art Hogan predicts the small-cap index will reach 1,800 by year-end, a 16% gain for the year and a further 10% climb from last week’s close.
This past Tuesday, May 29, 2018, shares of the WisdomTree Emerging Markets SmallCap Dividend Fund ETF (DGS) dipped below the 200-day moving average of $51.53. Shares were selling for a price as low as $51.50 a share. The low point that DGS has reached in the past 52 weeks is $45.1556 per share. The high point? $57.04.
Spectrum Global Solutions (OTC: SGSI), a single-source provider of end-to-end, next-generation wireless and wireline network solutions to the service provider (carrier) and corporate enterprise markets, reported more than $4 million for the first quarter and is tracking to exceed $30 million in revenue for the full year.
Why It Matters: SGSI is building an impressive backlog of new business, much of which gets booked as revenue in the coming months and quarters, which has given management great visibility into the overall potential for the year. With the favorable industry trends driving business demand, we don’t expect to see a change in the pace of new business wins the company has been announcing in recent months. This could lead to even further revenue growth in 2018 and beyond.
Key Quote: “We continue to seek acquisitions and strategic partnerships to grow our business with a goal of being uplisted to a national exchange by this time next year.” – Roger Ponder, CEO
What’s Next: SGSI’s market cap is only $1.6 million. The company is expected to generate upwards of $30 million in revenue in 2018. Even at a conservative valuation of 1x sales, the stock could still see gains of several hundred percent in the near-term. Add in the potential for further growth from acquisitions, and owning shares at current levels could be one of the best bargains of the year.
Disclosure
(Spectrum Global Solutions [OTC: SGSI] is a client of RedChip Companies, Inc. SGSI agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services.)
Esports Entertainment (OTCQB: GMBL), a licensed online gambling company with a specific focus on esports wagering and 18+ gaming, announced an agreement with PartnerMatrix, the first platform that enables online sportsbook and casino operators to run Affiliate System with Agent functionality and Agent System with Affiliate functionality.
Key Quote: “We are excited to have partnered with Partner Matrix and can’t wait to benefit from their well-built affiliate and agent system, which will allow us to track everything in one place. PartnerMatrix is highly focused on affiliate manager and administrator comfort. It gives us an opportunity to reach each angle of the affiliate program and successfully manage all the operations. This will be especially important given the pace of esports teams signing up as affiliates, as well as the onboarding of streamer affiliates.” – Grant Johnson, CEO
What’s Next: Under the terms of the agreement, the integration of the PartnerMatrix platform will be expedited. This is an important step forward for the company. With more than 50 esports teams signed up as affiliates, and even more than that signed at gamescom 2017 alone, a platform like PartnerMatrix is critical to managing this rapidly expanding network. The easier it is for affiliates to work with GMBL, the more traffic GMBL is likely to get, which ultimately leads to sustainable revenue growth.
Disclosure
(Esports Entertainment Group, Inc. [OTCQB: GMBL] is a client of RedChip Companies, Inc. GMBL agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services.)
West Coast Ventures Group Corp. (OTCQB: WCVC), which wholly owns fast-casual dining concept Illegal Burger, offering hand-crafted burger + bar (menu also includes chicken, salads, and specialty desserts), announced today the Company recently signed a letter of intent for a new Illegal Burger restaurant in a premier high-volume location in one of Denver's busiest trade areas.
Key Quote: "This is an exceptional opportunity to capture a dense white-collar day and evening population with high-income residential demographics. The new location sits between two nationally recognized hotels, Hilton and Residence Inn, with high-volume shopping and dining traffic. Sales in this location already exceeded $900,000 before conversion to the Company’s Illegal Burger brand. What is also very important to our model is that the location will provide 2000 sq. ft. of indoor seating and 350 sq. ft. of patio seating," Jim Nixon, CEO, WCVC.
The Backstory: Based in Denver, Colo., West Coast Ventures Group Corp. develops, owns and operates two contemporary restaurant concepts: Illegal Burger, a quick-casual burger + bar concept, and El Senor Sol, a full-service fresh Mexican restaurant. Led by seasoned restaurant entrepreneurs, WCVC management is committed to scaling both modern sustainable concepts into national franchise models operating metro-styled restaurants serving only the finest and freshest natural ingredients. The Company generates gross annual sales of $2,725,000.
Disclosure
(West Coast Ventures Group Corp. [OTCQB: WCVC] is a client of RedChip Companies, Inc. WCVC has agreed to pay RedChip Companies, Inc. 150,000 shares of Rule 144 stock and a monthly cash fee for 6 months of RedChip investor awareness services and consulting services.)
215 words
Quote of the Week
"Look at what you can afford to lose, it's a numbers game."
- Manager of MidSouth Investor Fund
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov.
